2 Information about palbociclib
Marketing authorisation indication
2.1 Palbociclib (Ibrance, Pfizer) is indicated 'for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer:
-
in combination with an aromatase inhibitor;
-
in combination with fulvestrant in women who have received prior endocrine therapy.
In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist'.
Dosage in the marketing authorisation
2.2 The dosage schedule is available in the summary of product characteristics for palbociclib.
Price
2.3 The company's list price is £2,950 per 21-pack of 75 mg, 100 mg or 125 mg capsules (excluding VAT; BNF online, accessed July 2022). The average cost of a course of combination treatment at list price is £6,170.70 for the loading dose and £5,126.42 for the following cycles. The company has a commercial arrangement. This makes palbociclib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.